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Background. Since cryoprecipitate, ﬁbrinogen concentrate, or recombinant activated factor VII is not approved by public medical
insurance in Japan, we retrospectively assessed blood product usage in patients with obstetric hemorrhage at our tertiary obstetric
center. Material and Methods. 220 patients with obstetric hemorrhagic disorders who underwent blood product transfusion in
our institution during a 5-year period were reviewed for the types and volumes of blood products transfused. Results. There was
a signiﬁcant positive correlation (P<0.001) between the volume of RCC (red blood cell concentrate) transfused and that of
FFP (fresh frozen plasma), irrespective of underlying obstetric disorders. The median of FFP to RCC ratio in each patient was
1.3–1.4, when 6 or more units of RCC were transfused. Conclusions. In transfusion for massive obstetric hemorrhage in terms of
appropriate supplementation of coagulation factors, the transfusion of RCC : FFP = 1 : 1.3–1.4 may be desirable.
1.Introduction
In the world, obstetric hemorrhage is the most common
cause of maternal death, causing 24% of, or an esti-
mated 127,000, maternal deaths annually [1]. It has also
been reported that massive (2,000mL or more) and life-
threatening obstetric hemorrhage occurs in 3–5% [2]a n d
0.1% [3] of deliveries, respectively, and blood product
transfusion is required in 0.3–1% [2, 4]. Also in Japan,
obstetrichemorrhageaccountcauses25%ofmaternaldeaths
[5] and massive obstetric hemorrhage (MOH) occurs in
1.1% of deliveries [6].
Intheterminalstageofpregnancy,wherethecoagulation
system is enhanced and the ﬁbrinolysis system is inhibited
[7, 8], MOH may be apt to induce consumptive loss
of coagulation factors, which causes further hemorrhage,
forming a vicious circle such as disseminated intravascular
coagulation (DIC) [9]. Accurate evaluation of blood loss
is important to determine whether transfusion should be
performed, but it is diﬃcult in obstetric hemorrhage [10–
12]. In addition, high-level capacity of pregnant women
to tolerate obstetric hemorrhage [13, 14] masks changes
in their vital signs, resulting in a delay in the detection
and treatment of hypovolemia, which causes further hemor-
rhage and hemorrhagic shock. Therefore, the comprehensive
evaluation of not only blood loss but also the cause of
hemorrhage, a patient’s medical condition, age, vital signs,
andbloodbiochemicaldataisrequiredtodeterminewhether
transfusion is necessary [15].
Understanding the above-mentioned speciﬁcity of
obstetric hemorrhage is also required for appropriate
blood product support, which can eﬀectively improve its
pathophysiological condition, reduce the risk of DIC, and
avoid the aggravation of hemorrhagic shock [16]. However,
in Japan, “Principles for blood transfusion therapy” and
“Principles of the use of blood products” [17] proposed by
the Japanese Ministry of Health, Labour and Welfare give
little consideration to the pathophysiological mechanism or2 ISRN Obstetrics and Gynecology
no standard for the appropriate dosage of blood product
transfusion speciﬁc to obstetric hemorrhage. Therefore, we
retrospectively reviewed blood product administration in
patients with obstetric hemorrhage at our tertiary obstetric
center for a 5-year period and discuss appropriate dosage of
blood product transfusion for obstetric hemorrhage.
2.MaterialandMethods
2.1. Subjects. Between January 1, 2004, and December
31, 2008, 243 obstetric patients underwent blood product
transfusion in our tertiary perinatal institution, Saitama
Medical Center/Saitama Medical University, which is only
general medical institution for tertiary perinatal care in
Saitamaprefecturewithpopulationof7.2million.Theirdata
were manually abstracted by our research staﬀsf r o mo u r
medical records, anonymized in an unlinkable fashion prior
to our investigation, which exempted us from institutional
review board approval according to “Ethical principles for
etiological studies” [18] proposed by the Japanese Ministry
of Health, Labour and Welfare.
Blood products involved in this study are red cells
concentrates (RCC), fresh-frozen plasma (FFP), and platelet
concentrates (PC). Two units of RCC (approximately
140mL/unit), 3 units of FFP (approximately 80mL/unit),
and 2 units of PC (approximately 20mL/unit) are derived
from 400mL of whole blood, respectively, in this study.
2.2.OurManagementPrinciplesforBloodProductTransfusion
(Table 1). Since blood loss in vaginal delivery or Caesare-
an section is diﬃcult to evaluate accurately [11, 12]a n d
hemoglobin (Hb) concentration necessary to maintain
appropriate hemodynamics and oxygen supply is ≥7g/dL
[19, 20], Hb concentration <7g/dL was determined to be
an indication for blood product transfusion in principle.
In addition to this principle, the patient’s age, medical
condition, state of hemorrhage, and blood test data were
taken into consideration [8, 15]. Since the transfusion for
patients with an Hb concentration ≥7g/dL and stable vital
signs may lead to excessive transfusion, RCC transfusion
was performed with a goal Hb concentration of 7-8g/dL
[21].FFPwasconcomitantlytransfuseduntilthecoagulation
function normalizes [9, 22]. We did not have any rule in
advance to deﬁne the proportion of FFP to RCC in the
present study.
Cryoprecipitate, ﬁbrinogen concentrate, or recombinant
activated factor VII was not administered in general, since
they are not approved or paid by public medical insurance in
Japan.
2.3. Evaluated Items. The following items were retrospec-
tively evaluated: underlying disorders which required blood
product transfusion, types of blood product and their trans-
fused volume, and data of hemoglobin (Hb) concentration,
percent prothrombin activity (%PT; normal range: 84–
117% in our institution), activated partial thromboplastin
time (aPTT; 25–36sec), and ﬁbrinogen concentration (150–
400mg/dL) within 30 minutes before blood transfusion.
Table 1: Our transfusion management principles.
(1) While evaluating the bleeding state, consumed coagulation
factors are rapidly supplemented until the coagulation function
normalizes [9, 22]
(2) With the above as a goal, 4–6 units of FFP are transfused at a
time, and the coagulation function is evaluated after each
transfusion
(3) Stabilization of the vital signs
(4) RCC transfusion is performed to achieve an Hb level of
7-8g/dL as a goal
(5) PC transfusion is performed to achieve a platelet count above
50,000/mm3 as a goal
(6) Cryoprecipitate, as well as speciﬁc coagulation factor
preparations, is not administered in general
Table 2:Demographicsofobstetricpatientswithbloodtransfusion
(n = 243).
Age in years, mean ± SD 32.1 ±4.7
Gestational age in weeks, mean ± SD 35.3 ±4.9
Primipara, n (%) 95 (39.1)
Multiple pregnancy, n (%) 14 (5.8)
Cesarean delivery, n (%) 164 (67.5)
Assisted vaginal delivery, n (%) 26 (10.7)
Blood test data were excluded for further statistical analyses
whentheywereobtained afterblood productwastransfused.
Prothrombin activity was assayed by STA-R Evolution
(Roche Diagnostics), a fully automated coagulation analyzer.
Clotting times were converted to percent normal plasma
prothrombin activity from a log-log standard curve prepared
with dilutions of control pooled plasma [23].
2.4. Statistical Analyses. The presence or absence of correla-
tions was analyzed by JMP (SAS Institute) software employ-
ing Spearman’s rank correlation coeﬃcient, and equality of
parameters among groups was analyzed employing Kruskal-
Wallis one-way analysis of variance by ranks because each
parameter did not show normal distribution. In each test,
P<0.05 was regarded as signiﬁcant.
3. Results
3.1. Obstetric Patients Who Underwent Blood Product Trans-
fusion (Table 2). We have experienced 243 obstetric patients
who underwent blood product transfusion, consisting of 164
(67%) delivered by Cesarean section and 79 (33%) delivered
vaginally. Eighty-two (34%) women were transported to
our institution in their puerperium for our specialized
management of obstetric hemorrhage. For 8 patients who
had blood transfusion prior to or during transfer, we
included the data on transfusion using their medical record
of transfer source institution.
We had one patient who died with amniotic ﬂuid
embolism resulting in severe coagulopathy and multipleISRN Obstetrics and Gynecology 3
Table 3: Obstetric hemorrhagic disorders with blood transfusion
(n = 220).
n (%)
Uterine atony 57 (25.9)
Genital tract trauma including uterine rupture/injury 51 (23.2)
Placental abruption 48 (21.8)
Placenta previa without acreta/increta/percreta 30 (13.6)
Placenta previa with acreta/increta/percreta 13 (5.9)
Uterine inversion 5 (2.3)
HELLP syndrome 15 (6.8)
Amniotic ﬂuid embolism 1 (0.5)
organ failure and one vegetative patient with severe HELLP
syndrome resulting in hypoxic encephalopathy.
Two hundred and twenty (91%) patients underwent
blood transfusion for obstetric hemorrhage, while 17 (7%)
patients for hematological disorders during pregnancy such
as idiopathic thrombocytopenic purpura (ITP), myelodys-
plastic syndrome (MDS), and leukemia. Four other patients
underwent blood transfusion for major disorders during
pregnancy such as cerebral infarction, gastric cancer, colon
cancer, and head injury. One pregnant woman with cardiac
dysfunction and one with no routine checkup but severe
anemia had blood transfusion in their emergency Cesarean
delivery.
3.2. Obstetric Indications of Blood Transfusion (Table 3).
Table 3 shows the 220 cases with obstetric hemorrhage that
required blood product transfusion. Most of the cases
underwent blood transfusion in their peripartum, except for
a few cases who had massive hemorrhage several days after
their delivery.
Some of the uterine atony cases resulted from retained
placental tissue or overdistension due to multiple pregnancy.
Genital tract trauma was noted in the vaginal wall, cervix,
and/or uterine body (uterine rupture was detected in 6
cases). Thirteen cases of placenta previa were complicated by
placenta acreta, increta, or percreta.
3.3. Blood Product Transfusion for Obstetric Indications.
Table 4 shows the number of cases and median volumes
for each blood product transfused for the 220 cases with
obstetric hemorrhage shown in Table 3. No cryoprecipitate,
ﬁbrinogen concentrate, or recombinant factor VII was
administered. Autologous whole blood was transfused for 24
patientswithplacentapreviawithorwithoutplacentaacreta,
increta, or percreta. These patients who had autologous
blood transfusion were excluded for the analysis.
In 196 patients with obstetric hemorrhage who under-
went only allogenic transfusion, there was a signiﬁcant
positive correlation (P<0.001) between the volume of
RCC transfused and that of FFP (Figure 1). This signiﬁcant
positive correlation was shown irrespective of underlying
obstetric disorders (Table 5).
A ratio of total transfused units of FFP to RCC was 2.1
(3,550/1,665) in the 196 patients with allogenic transfusion
Table 4: Blood products transfused for obstetric hemorrhage (n =
220).
Blood product n (%) Median units (range)
Red cell concentrate 188 (85.5) 8 (2–50)
Fresh frozen plasma 203 (92.3) 14 (2–116)
Platelet concentrate 62 (28.2) 20 (10–80)
Autologous whole blood 24 (10.9) 3 (1–8)
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Figure 1: Correlation between the volume of RCC and FFP in
obstetrichemorrhagepatientswithallogenictransfusion(n = 196).
A signiﬁcant positive correlation was observed between the volume
of RCC and that of FFP, as also shown in Table 5. Patients who
underwent autologous transfusion were excluded. An outlier with
amniotic ﬂuid embolism who had 50 units of RCC and 116 units of
FFP was also excluded.
alone. The median of FFP/RCC ratio for each patient was
2.0 in total (Table 5), and 2.1 and 2.0 in subgroups with
moderate (6–9 units) and massive (10 units or more) RCC
transfusion, respectively (Table 6). The median of FFP/RCC
ratio was not signiﬁcantly diﬀerent between underlying
obstetric disorders, but 2.0 or more except for uterine atony
(Table 5).
3.4. Comparison of Blood Test Data among Underlying Obstet-
ric Disorders. Next, we compared Hb concentration, per-
cent prothrombin activity (%PT), aPTT, and ﬁbrinogen
concentration immediately before blood transfusion among
underlying obstetric disorders which required blood product
transfusion. From the 220 obstetric disorder cases, 8 patients
who had our blood tests only after transfusion were excluded
for the analysis. One patient with amniotic ﬂuid embolism
was also excluded.
As shown in Figure 2, aPTT was not signiﬁcantly diﬀer-
ent among obstetric disorders. Hb concentration was sig-
niﬁcantly higher in HELLP syndrome compared with other4 ISRN Obstetrics and Gynecology
Table 5: Signiﬁcant positive correlation between RCC and FFP and an FFP/RCC ratio in each obstetric hemorrhagic disorder.
n Spearman’s rank correlation coeﬃcient (ρ) P FFP/RCC∗
Uterine atony/inversion 62 0.7843 <0.0001 1.5 (1.2–2.5)
Genital tract trauma 51 0.7841 <0.0001 2.3 (1.5–2.9)
Placental abruption 48 0.7818 <0.0001 2.3 (1.5–3.0)
Placenta previa 19 0.7765 <0.0001 2.0 (1.1–2.1)
HELLP syndrome 15 0.5290 0.0426 2.0 (1.9–2.8)
Total 196 0.7769 <0.0001 2.0 (1.4–2.5)
∗Data shown are median (interquartile range).
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Figure 2: Hemoglobin (Hb) concentration, percent prothrombin activity (%PT), activated partial thromboplastin time (aPTT), and
ﬁbrinogen concentration immediately before blood transfusion in each obstetric hemorrhagic disorder (n = 211). Box plot graphs represent
the median value as well as the upper and lower quartiles. The line across the middle of the box identiﬁes the median sample value. The
whiskers extend from the ends of the box to the outermost data point. The thick lines denote the mean values. Diﬀerent superscript letters
(a, b, c) denote signiﬁcant diﬀerence at P<0.05. Patients were excluded as mentioned in the text.ISRN Obstetrics and Gynecology 5
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Figure 3: Correlation between the volume of RCC transfused and Hb concentration or %PT in obstetric hemorrhage patients (n = 187).
A signiﬁcant negative correlation was observed between the volume of RCC transfused and Hb (a), or RCC and %PT (b). Patients were
excluded as mentioned in the text.
Table 6:FFPtransfusionvolumeandanFFP/RCCratioinobstetric
hemorrhage patients with minimal, moderate, and massive RCC
transfusion.
RCC transfusion n FFP (units)∗ FFP/RCC∗
None 24 5 (4–8) —
Minimal (2–4 units) 49 6 (4–8) 1.5 (1.0–3.0)
Moderate (6–9 units) 53 14 (10–20) 2.0 (1.3–2.7)
Massive (10- units) 70 30 (20–42) 2.1 (1.5–2.5)
∗Data shown are median (interquartile range).
disorders. %PT in placental abruption was not signiﬁcantly
diﬀerent from those in uterine atony/inversion or genital
tract trauma, but signiﬁcantly lower compared with placenta
previa and HELLP syndrome. Fibrinogen concentration in
placental abruption was signiﬁcantly lower, and that in
HELLPsyndromewassigniﬁcantlyhighercomparedtoother
disorders.
3.5. Correlation between Data of Blood Tests and the Volumes
of Blood Products Transfused. To clarify the characteristics of
hemorrhage in total or each underlying obstetric disorders,
we evaluated the possible correlation between data from
blood tests and the volumes of blood products transfused. As
mentioned previously, 32 patients who had our blood tests
only after transfusion or autologous blood transfusion were
excluded for the analysis. One maternal death with amniotic
ﬂuid embolism was also excluded since severe coagulopathy
resulting in MOF was not controlled by massive blood
product transfusion.
3.5.1. Correlation between the Volume of RCC Transfusion
and Hb Concentration or %PT. In the 187 obstetric disorder
patients, there was a signiﬁcant negative correlation (P<
0.001) between the volume of RCC transfused and Hb
concentration immediately before transfusion (Figure 3).
This signiﬁcant negative correlation was shown irrespective
of underlying obstetric disorders except for placenta previa
(data not shown).
Similarly, there was a signiﬁcant negative correlation
(P<0.001) between the volume of RCC transfused and
%PT (Figure 3). This signiﬁcant negative correlation was
shown irrespective of underlying obstetric disorders except
for placenta previa and HELLP syndrome (data not shown).
3.5.2. Correlation between the Volume of FFP Transfusion and
%PT or Fibrinogen Concentration. Also in FFP transfusion,
there was a signiﬁcant negative correlation (P<0.001)
between the volume of FFP transfused and %PT immedi-
ately before transfusion (Figure 4). This signiﬁcant negative
correlation was shown irrespective of underlying obstetric
disorders except for placenta previa (data not shown).
Similarly,therewasasigniﬁcantnegativecorrelation(P<
0.001) between the volume of FFP transfused and ﬁbrinogen
concentration (Figure 4). This signiﬁcant negative correla-
tion was shown irrespective of underlying obstetric disorders
except for placenta previa and HELLP syndrome (data not
shown).
4. Discussion
From 2004 to 2008, the incidence of blood product
transfusion for obstetric patients in our tertiary perinatal6 ISRN Obstetrics and Gynecology
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Figure 4: Correlation between the volume of FFP transfused and %PT or ﬁbrinogen concentration in obstetric hemorrhage patients (n =
187).AsigniﬁcantnegativecorrelationwasobservedbetweenthevolumeofFFPtransfusedand%PT(a),orFFPandﬁbrinogen(b).Patients
were excluded as mentioned in the text.
institution was 4.6% (243/5,311), which was much higher
than previously reported incidences, 0.3–1% [2–4]. In these
patients who had blood product transfusion, the percentage
of patients with 6 or more units of RCC was 57% (138/243),
which was also higher than previously reported, 32–42%
[2, 4, 24]. This may be because our institution is only general
medical institution for tertiary perinatal care in Saitama
prefecture with population of 7.2 million and has accepted
obstetric patients with life-threatening conditions.
Of the 220 patients with obstetric hemorrhage who
underwent blood product transfusion (Table 3), FFP was
transfused for 92.3% (203/220) (Table 4), suggesting impor-
tanceofcoagulationfactorsinbloodtransfusionforobstetric
hemorrhage. In the patients with obstetric hemorrhage who
underwent only allogenic transfusion, there was a signiﬁcant
positive correlation between the volume of RCC transfused
and that of FFP (Figure 1) irrespective of underlying obstet-
ricdisorders(Table 5).AratiooftotaltransfusedunitsofFFP
to RCC and the median of FFP/RCC ratio in each patient
was 2.1 and 2.0 (Table 5), respectively. Moreover, the median
FFP/RCC ratio was 2.0 and 2.1 in subgroups with moderate
and massive RCC transfusion, respectively (Table 6). Since
twounitsofRCCand3unitsofFFParederivedfrom400mL
ofwholeblood,respectively,inthisstudy,theRCC:FFPratio
of 1:2.0–2.1 in units is equivalent to 1:1.3–1.4 when these
volumes are converted to whole blood. This RCC:FFP ratio
of 1:1.3–1.4 is almost consistent with the report of Borgman
et al. who recommended the transfusion of RCC and plasma
at a ratio of 1:1.4 for massive hemorrhage [25].
To evaluate possible diﬀerences among obstetric hemor-
rhagic disorders in their pathophysiological condition which
may aﬀect the volumes of RCC and FFP transfused, we
compared Hb concentration, %PT, aPTT, and ﬁbrinogen
concentration immediately before blood transfusion. Pla-
cental abruption causes dissection of blood at the decidual-
placentalinterface,resultinginentryofplacentaltissuefactor
into the circulation to promote thrombin generation which
eventually leads to disseminated intravascular coagulation
(DIC) [26]. As shown in Figure 2, ﬁbrinogen concentration
is signiﬁcantly lower in placental abruption compared with
other obstetric disorders, suggesting severer coagulopathy
than other obstetric disorders.
As mentioned previously, accurate evaluation of blood
loss is diﬃcult in obstetric hemorrhage [10–12], so compre-
hensive evaluation of not only blood loss but also the cause
of hemorrhage and blood test data is required to determine
the timing and volume of blood transfusion [15]. Moreover,
our present data lack some other important variables prior
to blood transfusion, such as rates and volumes of IV
ﬂuid resuscitation and use of surgical or pharmacologic
interventions. Nonetheless, as shown in Figure 3, there was
a signiﬁcant negative correlation between the volume of
RCC transfused and Hb concentration immediately before
transfusion. This signiﬁcant negative correlation was shown
in all obstetric disorders except for placenta previa. This
may be because for some patients with placenta previa the
interval between onset of hemorrhage and blood test was so
short that data did not reﬂect blood loss, and the transfusion
volume was determined by intraoperative blood loss count.
Similarly, there was a signiﬁcant negative correlation
betweenthevolumeofFFPtransfusedand%PTorbloodﬁb-
rinogen concentration (Figure 4), showing that patients withISRN Obstetrics and Gynecology 7
severer coagulation factor depletion required a larger volume
of FFP for its supplementation. Interestingly, there was a
signiﬁcant negative correlation also between the volume of
RCC transfused and %PT as data of coagulation system
tests (Figure 3), suggesting that coagulation dysfunction due
to coagulation factor depletion may result in even more
blood loss and increase in transfusion volume of not only
FFP but also RCC. These results are consistent with studies
showing an increase in blood loss due to secondary atonic
bleedingunlesscoagulationfactorsarerapidlysupplemented
[27], further dilution of coagulation factors and blood loss
resulting from RCC and extracellular ﬂuid supplementation
alone without coagulation factors to pregnant and puerperal
women with MOH [28], an increase in blood loss along
with a decrease in coagulation factors, particularly with
blood ﬁbrinogen level less than 200mg/dL [29], and the
indispensability of coagulation factorsupplementation when
the blood ﬁbrinogen level is ≤100mg/dL [30]. Appropri-
ate supplementation of coagulation factors normalizes the
coagulation function in the early stage and reduces not only
blood loss but also the volume of blood product transfusion
[22, 27, 28, 31].
According to Figures 3 and 4, it is also noted that con-
siderable number of patients with Hb, %PT, and ﬁbrinogen
values in the normal range were transfused with RCC and/or
FFP. This may be because above-mentioned comprehensive
evaluation of blood loss, cause of hemorrhage, vital signs,
underlying disorders, and so forth has led to the clinical
decision for blood product transfusion before the deteriora-
tion of their blood test values. On the other hand, Table 6
shows that 24 (12%) patients received FFP without RCC.
In these patients consisting of 5 with placental abruptions,
7 with uterine atonies, 1 with genital tract trauma, and 11
with HELLP syndromes, RCC transfusion was not required
since coagulation factors were promptly supplemented with
FFP and their Hb levels could be maintained above 7g/dL.
Although some retrospective analyses reported that a per-
centage of patients were inappropriately transfused [24, 32],
we believe that prompt decision making is inevitable to
avoid secondary atonic bleeding and DIC especially in life-
threatening obstetric hemorrhage.
In conclusion, for massive obstetric hemorrhage where
appropriate supplementation of coagulation factors is essen-
tial, the transfusion of RCC:FFP = 1:1.3–1.4 in terms
of whole blood is desirable according to our retrospective
analysis as well as previous report [25].
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